James T. Hippel
Net Worth
Last updated:
What is James T. Hippel net worth?
The estimated net worth of Mr. James T. Hippel is at least $47,352,365 as of 19 Dec 2023. He owns shares worth $589,374 as insider, has earned $29,662,991 from insider trading and has received compensation worth at least $17,100,000 in Bio-Techne Corporation.
What is the salary of James T. Hippel?
Mr. James T. Hippel salary is $1,710,000 per year as Executive Vice President of Fin. & Chief Financial Officer in Bio-Techne Corporation.
How old is James T. Hippel?
Mr. James T. Hippel is 54 years old, born in 1971.
What stocks does James T. Hippel currently own?
As insider, Mr. James T. Hippel owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | Executive Vice President of Fin. & Chief Financial Officer | 10,755 | $54.8 | $589,374 |
What does Bio-Techne Corporation do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
James T. Hippel insider trading
Bio-Techne Corporation
Mr. James T. Hippel has made 27 insider trades between 2015-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 47,289 units of TECH stock on 19 Dec 2023. As of 19 Dec 2023 he still owns at least 10,755 units of TECH stock.
Bio-Techne key executives
Bio-Techne Corporation executives and other stock owners filed with the SEC:
- Mr. Charles R. Kummeth (65) Chief Executive Officer, Pres & Director
- Mr. James T. Hippel (54) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Kim Kelderman (58) Pres of Diagnostics & Genomics
- Mr. Norman David Eansor (64) Advisor
- Ms. Brenda S. Furlow J.D. (67) Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer